During the Trading Day
| 1.38 |  -0.02 / -1.43% |
Data as of 3:59pm ET | Day’s Change | |
| 1.38 |  0.00 / 0.00% |
| Volume: 715.00 |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $105.2M |
Company Description
GTx, Inc. is a biopharmaceutical company. It engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for prostate and breast cancer, cancer supportive care, including prevention and treatment of cancer-related muscle wasting or cachexia, and other serious medical conditions. The company also develops selective androgen receptor modulators, a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia, as well as the potential to be used as a hormonal therapy for the treatment of metastatic breast cancer. Its lead SARM product candidate, enobosarm (GTx-024), has to date been evaluated in fourteen completed or ongoing clinical trials enrolling approximately 1,320 subjects, including in three Phase 2 and two Phase 3 clinical trials. GTx was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.
Employees
Shareholders
| Individual stakeholders | 63.08% |
| Other institutional | 5.86% |
| Mutual fund holders | 3.68% |
Top Executives
| Marc Steven Hanover | President, Chief Executive Officer, COO & Director |
| Jason T. Shackelford | CFO, CAO, Accounting Director & Controller |
| James T. Dalton | Chief Scientific Officer & Vice President |
| Mary Ann Johnston | VP-Medical Affairs & Clinical Operations |
| Henry Patton Doggrell | Secretary, Chief Legal Officer & Vice President |
.
